Abstracts tagged "quality of life"

Abstract Number: 1145 • ACR Convergence 2020
Implementation of Web-Based Patient-Reported Outcome Measures (PROMs) in SLE Clinical Care: A Multi-Center Prospective Cohort Study
Shanthini Kasturi¹, Lori Lyn Price¹, David Curtis², William Nowell³, Norma Terrin¹, Jane Salmon⁴, Lisa Mandl⁴ and Timothy McAlindon¹, ¹Tufts Medical Center, Boston, MA, ²Global Healthy Living Foundation, New York City, ³Global Healthy Living Foundation, New York City, NY, ⁴Hospital for Special Surgery, New York, NY
Background/Purpose: Patient-reported outcome measures (PROMs) are powerful tools which can highlight the patient experience of illness. Although PROMs are standard metrics in SLE clinical research,…
Abstract Number: 1900 • ACR Convergence 2020
The Clinical and the Functional Impact of Central Sensitization on Patients with Axial Spondyloarthritis
Feyza Nur Yücel¹ and Mehmet Tuncay Duruöz², ¹Marmara University School of Medicine PMR Department, Istanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey
Background/Purpose: To evaluate the impact of central sensitization (CS) on axial spondyloarthritis (AxSpA) patients’ clinical and functional situation and quality of life.Methods: Subjects with axSpA…
Abstract Number: 0405 • ACR Convergence 2020
Disease Activity and Quality-of-Life Outcomes in Patients with Behçet’s Syndrome Who Achieved and Maintained Oral Ulcer Complete Response with Apremilast Treatment
Gülen Hatemi¹, Alfred Mahr², Mitsuhiro Takeno³, Doyoung Kim⁴, Melike Melikoğlu¹, Sue Cheng⁵, Sven Richter⁵, Michele Brunori⁶, Maria Paris⁵, Mindy Chen⁵ and Yusuf Yazici⁷, ¹Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, ²Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ³Nippon Medical School, Graduate School of Medicine, Tokyo, Japan, ⁴Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, ⁵Amgen Inc., Thousand Oaks, ⁶Amgen Europe GmbH, Rotkreuz, Switzerland, ⁷New York University School of Medicine, New York
Background/Purpose: Recurrent, painful oral ulcers (OU) are common symptoms of Behçet’s syndrome that can impact daily activities and impair quality of life (QoL) (Kokturk A.…
Abstract Number: 1147 • ACR Convergence 2020
Development of a Digital Toolkit to Improve Quality of Life of Patients with Systemic Lupus Erythematosus: A Pilot Study
Jerik Leung¹, Ashish Shrestha¹, Jennifer Ra², Laura Brennan³, Alfred Kim⁴ and Elizabeth Baker¹, ¹Saint Louis University, College for Public Health and Social Justice, St. Louis, ²Washington University School of Medicine, Lake Forest, CA, ³Transtria, St. Louis, ⁴Washington University School of Medicine, St. Louis, MO
Background/Purpose: Individuals living with systemic lupus erythematosus (SLE) face a number of challenges in managing their condition. Initial interviews and community forums with SLE patients…
Abstract Number: 1967 • ACR Convergence 2020
Combating Rheumatologist Burnout: Use of Protocol Driven Medication Refill by Pharmacists
Eva Rottmann¹, Jonida Cote², Swana Thomas³, Dante Grassi¹, Joseph Chronowski¹, Lisa L. Schroeder¹, David Pugliese⁴ and Eric Newman¹, ¹Geisinger Medical Center, Danville, PA, ²Geisinger Medical Center, Danvile, PA, ³Geisinger Medical Center, Wilkes-Barre, PA, ⁴Geisinger Health System, Wilkes Barre, PA
Background/Purpose: Increased electronic health record (EHR) administrative workload is a great source of physician dissatisfaction. We embedded pharmacists into our Rheumatology team in 2019. This…
Abstract Number: 0422 • ACR Convergence 2020
Frailty and Health-Related Quality of Life in Patients with Polymyalgia Rheumatica
Sebastian Sattui¹, Deanna Jannat-Khah², Lindsay Lally¹, Sarah Lieber¹, Lisa Mandl¹ and Robert Spiera³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York City, NY, ³Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY
Background/Purpose: Frailty is a syndrome characterized by an increased vulnerability to stressors. Frailty and pre-frailty have been reported in 10% and 44%of community dwelling elderly,…
Abstract Number: 1210 • ACR Convergence 2020
Patient-Reported Outcomes Measurement Information System (PROMIS) Assessment of Response to Treatment with Golimumab IV or Infliximab in Rheumatoid Arthritis Patients: Results from a Phase 4 Study
Clifton Bingham III¹, Shelly Kafka², Shawn Black², Stephen Xu³, Wayne Langholff⁴ and Jeffrey R Curtis⁵, ¹Johns Hopkins University, Baltimore, MD, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: AWARE (Comparative & Pragmatic Study of Golimumab [GLM] Intravenous [IV] vs Infliximab [IFX] in RA) is a Phase 4 study designed to provide a…
Abstract Number: 1982 • ACR Convergence 2020
Quality of Life of Patients with Facial Cutaneous Lupus Erythematosus
Josef Symon Concha¹, Daisy Yan¹, Christina Bax², Adarsh Ravishankar³, Robert Borucki⁴, Rui Feng⁴ and Victoria Werth⁵, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Department of Dermatology, Philadelphia, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia
Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is an autoimmune skin disease that may occur with or without systemic lupus erythematosus (SLE). Active CLE lesions present with…
Abstract Number: 0570 • ACR Convergence 2020
The Patient Perspective on Using Digital Resources to Address Unmet Needs in Systemic Lupus Erythematosus
Jennifer Ra¹, Jerik Leung², Elizabeth Baker² and Alfred Kim¹, ¹Washington University School of Medicine, St. Louis, MO, ²Saint Louis University, College for Public Health and Social Justice, St. Louis
Background/Purpose: The clinical variability of systemic lupus erythematosus (SLE) caused by the unpredictability of flares contributes to patients experiencing a diminished sense of social support.…
Abstract Number: 1216 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study
Rieke Alten¹, William F. C. Rigby², Alena Pechonkina³, Zhaoyu Yin⁴, Ken Hasegawa⁴, Thijs Hendrikx⁵, Tatsuya Atsumi⁶ and Rene Westhovens⁷, ¹Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Gilead Sciences, Inc., Foster City, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan, ⁷University Hospitals Leuven, Belgium, Leuven, Belgium
Background/Purpose: In FINCH 3, filgotinib (FIL)—a potent, selective, oral JAK1 inhibitor1—in combination with methotrexate (MTX), demonstrated significant improvements in signs and symptoms of rheumatoid arthritis…
Abstract Number: 1984 • ACR Convergence 2020
Causal Pathways to Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the ReACCh-Out Cohort
Kiem Oen¹, Jiahao Tian², Thomas Loughin², Roberta Berard³, Mercedes Chan⁴, Ciaran Duffy⁵, Brian Feldman⁶, Adam Huber⁷, Deborah Levy⁸, Dax G. Rumsey⁹, Natalie Shiff¹⁰, Shirley Tse¹¹, Lori Tucker⁴, Karen Watanabe-Duffy⁵ and Jaime Guzman¹², ¹University of Manitoba, Toronto, ON, Canada, ²Simon Fraser University, Burnaby, BC, Canada, ³London Health Sciences Centre, London, ON, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Florida, Gainesville, FL, ¹¹SickKids, Toronto, ON, Canada, ¹²University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The relative roles of disease activity and disability as determinants of health-related quality of life (HRQoL) in children with JIA have been controversial; sometimes…
Abstract Number: 0061 • ACR Convergence 2020
Rheumatologists’ Attitudes Toward Palliative Care and Medical Assistance in Dying
Alexandra Saltman¹, Caroline McGuinty², Gursimran Chandhoke³, Simon Oczkowski⁴, Heather McDonald-Blumer¹, Ebru Kaya⁵ and Kirsten Wentlandt⁶, ¹University Health Network and Sinai Health System, University of Toronto Faculty of Medicine, Toronto, ON, Canada, ²Ottawa Heart Institute and University of Ottawa, Ottawa, ON, Canada, ³Lakeridge Health, Oshawa, ON, Canada, ⁴Juravinski Hospital and McMaster University, Hamilton, ON, Canada, ⁵University Health Network,, University of Toronto Faculty of Medicine, Toronto, ON, Canada, ⁶University Health Network, University of Toronto Faculty of Medicine, Toronto, ON, Canada
Background/Purpose: Despite major advances in the treatment of systemic rheumatic diseases, a population remains—including those with systemic vasculitis, inflammatory myositis and systemic sclerosis—who suffer from…
Abstract Number: 0652 • ACR Convergence 2020
Changes in Serum Urate, in the First 6-months of Initiation or Change of Urate-Lowering Therapy, Associate with Immediate Health-Related Quality of Life Outcomes in People with Gout
Ruth Topless¹, Tony Merriman¹, Siamak Noorbaloochi² and Jasvinder Singh³, ¹University of Otago, Dunedin, New Zealand, ²University of Minnesota, Minneapolis, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Few studies, if any, have found association of the biochemical cause of gout (high serum urate) with functional limitation and health-related quality of life…
Abstract Number: 1269 • ACR Convergence 2020
Evaluation of a Patient-reported Frailty Tool in Women with Systemic Lupus Erythematosus
Sarah Lieber¹, Stephen Paget¹, Jessica Berman¹, Medha Barbhaiya², Lisa Sammaritano², Kyriakos Kirou¹, John Carrino³, Musarrat Nahid⁴, Mangala Rajan⁴, Dina Sheira¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, ³Hospital for Special Surgery, Hackensack, NJ, ⁴Weill Cornell Medicine, New York
Background/Purpose: Frailty has been associated with increased disability and mortality in SLE. To our knowledge, no patient-reported frailty tool has been evaluated alongside a standard…
Abstract Number: 2011 • ACR Convergence 2020
Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study
Evgeny Nasonov¹, Saeed Fatenejad², Mariana Ivanova³, Diana Krechikova⁴, Sofia Kuzkina⁵, Alexey Maslyanskiy⁶, Tatiana Plaksina⁷, Mikhail Samsonov⁵, Marina Stanislav¹, Tamara Tyabut⁸, Irina Vinogradova⁹, Sergey Yakushin¹⁰, Elena Zonova¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, LLC, Charlotte, NC, ³UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways"”, Smolensk, Russia, ⁵JSC “R-Pharm”, Moscow, Russia, ⁶SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov", Saint Petersburg, Russia, ⁷SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", Nizhny Novgorod, Russia, ⁸Belarusian Medical Academy of Postgraduate Education, Minsk, Russia, ⁹Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Russia, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic, Novosibirsk, Russia, ¹²Stanford University Medical Center, Palo Alto, CA
Background/Purpose: We previously reported positive efficacy and safety results of olokizumab (OKZ), an interleukin-6-inhibitor, in patients with RA inadequately controlled by MTX (NCT02760368; CREDO-1) [Nasonov…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.